Aegerion starts Japanese Phase III trial of cholesterol drug


Aegerion Pharmaceuticals (AEGR) has started a Phase 3 Trial in Japan to evaluate its Lomitapide treatment for cutting low-density lipoprotein ("bad") cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

HoFH is a rare genetic disease that harms the ability of the body to remove LDL-C cholesterol. Sufferers often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.

The trial adds to a Phase III study that has been completed in the U.S. and other countries.

Last year, Aegerion received orphan drug designation in Japan for Lomitapide. (PR)

Comments (1)
  • Marek
    , contributor
    Comments (1516) | Send Message
     
    It's not that rare of a disease, due to recent dietary influences and processed foods moving to fructose with MSG,many people have lifelong struggles from an early age also due to early misunderstanding that it was the sugar proportion, not the fat, that was the bad guy in hyperlipidemia and hypercholesteremia. Good prospects to make significant money if it passes, bypass surgery aint cheap and metabolic syndrome is extremely widespread.
    10 Apr 2014, 10:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs